Literature DB >> 19769599

RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ).

Gregory M Chandler1, Dan V Iosifescu, Mark H Pollack, Steven D Targum, Maurizio Fava.   

Abstract

The low rate of response to antidepressants in treatment resistant depression (TRD) justifies studies of next-step therapies following a treatment failure. In TRD clinical trials, it is important to verify the accurate diagnosis of treatment resistance for all enrolled subjects using a reliable and valid instrument. Self-rated scales can reduce the impact of investigator bias and reduce the time burden for clinical researchers. The Massachusetts General Hospital (MGH) Antidepressant Treatment Response Questionnaire (ATRQ) is a self-rated scale used to determine treatment resistance in major depressive disorder (MDD). The ADAPT-A study is a multi-center double-blind, placebo-controlled study of low-dose aripiprazole adjunctive to ADT among outpatients with TRD. At the screening assessment, potential subjects completed the MGH ATRQ. The ADAPT-A medical monitors subsequently performed remote patient interviews and obtained detailed medication histories. The data obtained from the MGH ATRQ and by the medical monitors were compared for congruency. Of the 186 patients enrolled by the local sites, no subjects deemed treatment resistant by the MGH ATRQ were found to be nonresistant by the medical monitors. In 76.3% (n = 142) of the subjects, the number of failed adequate antidepressant trials reported by the MGH ATRQ was concordant with the data collected by medical monitors. In 16.1% (n = 30) of all cases, the medical monitors found a greater number of failed trials; in 7.5% (n = 14) of cases, the medical monitors found fewer failed medication trials. The discrepancy was by more than one medication trial in only 4.0% (n = 7) of cases. We found the MGH ATRQ to be relatively concordant in its assessment of treatment resistance in depression compared with independent clinical researchers. Although the MGH ATRQ tended to underreport the number of unsuccessful treatment trials relative to the clinical interviews, its accuracy in cases it detected was confirmed by raters.
© 2009 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19769599      PMCID: PMC6493891          DOI: 10.1111/j.1755-5949.2009.00102.x

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  12 in total

Review 1.  Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association.

Authors: 
Journal:  Am J Psychiatry       Date:  2000-04       Impact factor: 18.112

Review 2.  Diagnosis and definition of treatment-resistant depression.

Authors:  Maurizio Fava
Journal:  Biol Psychiatry       Date:  2003-04-15       Impact factor: 13.382

3.  Nonfinancial conflicts of interest in research.

Authors:  Norman G Levinsky
Journal:  N Engl J Med       Date:  2002-09-05       Impact factor: 91.245

4.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

5.  STAR*D: what have we learned?

Authors:  A John Rush
Journal:  Am J Psychiatry       Date:  2007-02       Impact factor: 18.112

6.  Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial.

Authors:  M Fava; D L Dunner; J H Greist; S H Preskorn; M H Trivedi; J Zajecka; M Cohen
Journal:  J Clin Psychiatry       Date:  2001-06       Impact factor: 4.384

Review 7.  The definition and meaning of treatment-resistant depression.

Authors:  H A Sackeim
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

8.  Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine.

Authors:  Madelaine M Wohlreich; Craig H Mallinckrodt; John G Watkin; Michael G Wilson; John H Greist; Pedro L Delgado; Maurizio Fava
Journal:  Ann Clin Psychiatry       Date:  2005 Oct-Dec       Impact factor: 1.567

9.  The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

Authors:  Robert M Berman; Ronald N Marcus; René Swanink; Robert D McQuade; William H Carson; Patricia K Corey-Lisle; Arif Khan
Journal:  J Clin Psychiatry       Date:  2007-06       Impact factor: 4.384

10.  The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study.

Authors:  Maurizio Fava; James M Martinez; John Greist; Lauren B Marangell; Eileen Brown; Lei Chen; Madelaine M Wohlreich
Journal:  Ann Clin Psychiatry       Date:  2007 Jul-Sep       Impact factor: 1.567

View more
  45 in total

1.  Fatigue as a residual symptom of depression.

Authors:  Steven D Targum; Maurizio Fava
Journal:  Innov Clin Neurosci       Date:  2011-10

2.  Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women: A Pilot Study.

Authors:  Laura E Dichtel; Maren Nyer; David Mischoulon; Maurizio Fava; Karen K Miller; Christina Dording; Lauren B Fisher; Cristina Cusin; Benjamin G Shapero; Paola Pedrelli; Allison S Kimball; Elizabeth M Rao
Journal:  J Clin Psychiatry       Date:  2020-06-09       Impact factor: 4.384

3.  A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder.

Authors:  Dawn F Ionescu; Maurizio Fava; Daniel Ju Hyung Kim; Lee Baer; Richard C Shelton; Cristina Cusin
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

4.  Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study.

Authors:  Laura E Dichtel; Linda L Carpenter; Maren Nyer; David Mischoulon; Allison Kimball; Thilo Deckersbach; Darin D Dougherty; David A Schoenfeld; Lauren Fisher; Cristina Cusin; Christina Dording; Nhi-Ha Trinh; Paola Pedrelli; Albert Yeung; Amy Farabaugh; George I Papakostas; Trina Chang; Benjamin G Shapero; Justin Chen; Paolo Cassano; Emily M Hahn; Elizabeth M Rao; Roscoe O Brady; Ravinder J Singh; Audrey R Tyrka; Lawrence H Price; Maurizio Fava; Karen K Miller
Journal:  Am J Psychiatry       Date:  2020-07-14       Impact factor: 18.112

5.  Predictors of Depressive Relapse in Women Undergoing Infertility Treatment.

Authors:  Marlene P Freeman; Hang Lee; Gina M Savella; Alexandra Z Sosinsky; Samantha P Marfurt; Shannon K Murphy; Lee S Cohen
Journal:  J Womens Health (Larchmt)       Date:  2018-08-01       Impact factor: 2.681

Review 6.  Investigational drugs in recent clinical trials for treatment-resistant depression.

Authors:  Ricardo P Garay; Carlos A Zarate; Thomas Charpeaud; Leslie Citrome; Christoph U Correll; Ahcène Hameg; Pierre-Michel Llorca
Journal:  Expert Rev Neurother       Date:  2017-01-29       Impact factor: 4.618

7.  Demonstrating test-retest reliability of electrophysiological measures for healthy adults in a multisite study of biomarkers of antidepressant treatment response.

Authors:  Craig E Tenke; Jürgen Kayser; Pia Pechtel; Christian A Webb; Daniel G Dillon; Franziska Goer; Laura Murray; Patricia Deldin; Benji T Kurian; Patrick J McGrath; Ramin Parsey; Madhukar Trivedi; Maurizio Fava; Myrna M Weissman; Melvin McInnis; Karen Abraham; Jorge E Alvarenga; Daniel M Alschuler; Crystal Cooper; Diego A Pizzagalli; Gerard E Bruder
Journal:  Psychophysiology       Date:  2017-01       Impact factor: 4.016

8.  An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor- or Serotonin-Norepinephrine Reuptake Inhibitor-Resistant Depression in Adult Women.

Authors:  Brent M Kious; Hana Sabic; Young-Hoon Sung; Douglas G Kondo; Perry Renshaw
Journal:  J Clin Psychopharmacol       Date:  2017-10       Impact factor: 3.153

9.  Beneficial effects of adjunctive aripiprazole in major depressive disorder are not dependent on antidepressant therapy history: a post hoc analysis of 3 randomized, double-blind, placebo-controlled trials.

Authors:  David L Dunner; Kimberly K Laubmeier; George Manos; Robert A Forbes; Ross A Baker; Robert M Berman
Journal:  Prim Care Companion CNS Disord       Date:  2012-11-22

10.  Current nosology of treatment resistant depression: a controversy resistant to revision.

Authors:  Michele Fornaro; Patricia Giosuè
Journal:  Clin Pract Epidemiol Ment Health       Date:  2010-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.